This recombinant monoclonal antibody is developed as a research-grade biosimilar to SRK-181, designed to specifically target transforming growth factor beta 1 (TGFB1). TGFB1 is a multifunctional cytokine that regulates cellular proliferation, differentiation, immune responses, and extracellular matrix production. In normal physiology, TGFB1 maintains tissue homeostasis and immune tolerance, but aberrant TGFB1 signaling contributes to fibrotic diseases, tumor progression, and immune evasion in cancer. The protein exists in a latent form that requires context-specific activation, making it a critical therapeutic target in oncology and fibrosis research.
SRK-181 is a context-specific anti-TGFB1 antibody that selectively inhibits TGFB1 activation in disease-associated environments while preserving normal physiological TGFB1 function. This unique mechanism distinguishes it from pan-TGFB1 inhibitors and has shown promise in preclinical models of cancer and fibrosis. This biosimilar antibody serves as a valuable research tool for investigating TGFB1 biology, exploring context-dependent signaling mechanisms, and studying therapeutic strategies targeting the tumor microenvironment and fibrotic pathways.
Email: support@cusabio.com
Distributors Worldwide